"As specialty medications
continue to be a larger proportion of drug spend on both the medical and
pharmacy benefits, our novel approach to [bring] better pricing, improved
clinical outcomes and improved patient satisfaction is what the marketplace
needs and will continue to need."
— Dea Belazi, CEO of specialty PBM AscellaHealth LLC, talked
with AIS's RADAR on Drug
Benefits about UnitedHealth Group's plans to purchase Diplomat
Pharmacy, Inc. and how it could impact other specialty PBMs.
No comments:
Post a Comment